Theriva Biologics to Provide Update at A.G.P. 2024 Virtual Healthcare Conference

Theriva Biologics, a clinical-stage company, is set to provide a corporate update and participate in a fireside chat at the A.G.P. 2024 Virtual Healthcare Conference, discussing its progress and future plans for its novel oncolytic adenovirus platform and other therapeutic candidates targeting cancer and related diseases. The event will take place on May 21, 2024, and will be webcast live, offering insights into the company's strategy and upcoming milestones in the field of cancer research and treatment. This description focuses on the primary topic (Theriva Biologics' participation in the A.G.P. conference), main entities (Theriva Biologics, A.G.P. conference), context (virtual healthcare conference), significant actions (corporate update and fireside chat), and objective details (date, webcast, and focus on cancer research and treatment). This information will guide the AI in creating an accurate and meaningful visual representation of the article's content.

author-image
Trim Correspondents
New Update
Theriva Biologics to Provide Update at A.G.P. 2024 Virtual Healthcare Conference

Theriva Biologics to Provide Update at A.G.P. 2024 Virtual Healthcare Conference

Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics for cancer and related diseases, announced that its management team will provide a corporate update and participate in a fireside chat at the A.G.P. 2024 Virtual Healthcare Conference on Tuesday, May 21, 2024 at 7:30 AM ET.

Why this matters: This update has significant implications for the development of cancer treatments and the future of healthcare. As Theriva Biologics continues to advance its novel oncolytic adenovirus platform, it could lead to breakthroughs in cancer research and improved patient outcomes.

During the fireside chat, Theriva's management will discuss the company's progress and future plans. The presentation will be webcast live and archived for 90 days on Theriva's website. Investors and interested parties can access the webcast via a link that will be posted on the company's website.

Theriva Biologics is advancing an oncolytic adenovirus platform designed for intravenous, intravitreal, and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient's immune system. The company's lead candidates include VCN-01, an oncolytic adenovirus, SYN-004 (ribaxamase) designed to prevent microbiome damage, and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP).

For more information, please contact Chris Calabrese, Investor Relations at LifeSci Advisors, LLC, at ccalabrese@lifesciadvisors.com or 917-680-5608.

The A.G.P. conference provides Theriva Biologics an opportunity to update investors on its pipeline progress as the company continues to advance its novel oncolytic adenovirus platform and other therapeutic candidates targeting cancer and related diseases. With the live webcast, a broader audience will be able to hear directly from Theriva's management team about the company's strategy and upcoming milestones.

Key Takeaways

  • Theriva Biologics to present at A.G.P. 2024 Virtual Healthcare Conference on May 21, 2024.
  • Management to discuss progress and future plans for oncolytic adenovirus platform.
  • Webcast will be available live and archived for 90 days on Theriva's website.
  • Theriva's platform aims to trigger tumor cell death and promote anti-tumor response.
  • Lead candidates include VCN-01, SYN-004, and SYN-020 for cancer and related diseases.